Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more

Jason Meyenburg has left Orchard Therapeutics plc (NASDAQ:ORTX) as CCO to become CEO of ophthalmic disease company Gemini Therapeutics Inc. (Cambridge, Mass.). Orchard President and CEO Mark Rothera will assume global commercial leadership responsibilities in the interim while the gene therapy company searches for a permanent successor.

Cancer company Black Diamond Therapeutics Inc. (Cambridge, Mass.) hired Thomas Leggett as CFO. Leggett was CFO of Axcella

Read the full 654 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE